Egrifta (Tesamorelin) + MK-677 (Ibutamoren) Stack: Complete Protocol

What Are Tesamorelin and MK-677 and Why Stack Them?

Tesamorelin is a stabilized analog of endogenous growth-hormone-releasing hormone (GHRH). The FDA approved it in 2010 under the brand name Egrifta for HIV-associated lipodystrophy. MK-677 (ibutamoren) is a small-molecule, orally bioavailable ghrelin receptor (GHSR-1a) agonist developed by Merck in the 1990s. It mimics ghrelin's ability to stimulate GH secretion without the intravenous administration ghrelin itself requires.

The rationale for combining them is mechanistic. GHRH and ghrelin act at different receptor classes and have additive or synergistic effects on pituitary GH output in animal and small human studies. A 1997 study published in the Journal of Clinical Endocrinology and Metabolism found that GHRH and GHRP-6 (a peptide ghrelin mimetic) together produced GH peaks roughly three to five times higher than either compound alone in healthy adults [1]. MK-677 acts through the same GHSR-1a receptor as GHRP-6, making the mechanistic analogy reasonable, though not identical.

Tesamorelin: What the Phase III Data Show

The GHRH analog is backed by Phase III evidence. In two 26-week, placebo-controlled trials (N=816 combined) in HIV-positive patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by a mean of 18% vs. 5% placebo (P<0.001) and raised IGF-1 from a mean of 144 ng/mL to 284 ng/mL [2]. IGF-1 stayed within normal age-adjusted ranges in most participants at that dose. Glucose rose modestly, with HbA1c increasing by a mean of 0.12% over 26 weeks.

MK-677: What the Phase II Data Show

MK-677 reached Phase II before development stalled. In a 12-month randomized trial (N=65 elderly adults), 25 mg oral MK-677 daily raised mean IGF-1 by 39.9% from baseline while increasing lean body mass by 1.6 kg and fat mass by 0.8 kg [3]. Fasting glucose rose significantly in that cohort. A separate 2-year study in 292 hip-fracture patients found MK-677 25 mg/day increased IGF-1 by 84% but did not reduce re-fracture rates; one subgroup showed a non-significant increase in congestive heart failure events [4].

Why the Stack Has No RCT Data

No published RCT has randomized participants to tesamorelin plus MK-677. The protocol below synthesizes mechanism, the individual trial data above, and structured practitioner reports. Every recommendation here carries a lower evidence grade than the individual drug data. Clinicians should treat dosing guidance as a starting framework, not a validated regimen.

How the Two Agents Interact Mechanistically

Tesamorelin binds pituitary GHRH receptors, increasing cyclic AMP and driving GH secretion in discrete pulses that mirror the body's natural ultradian rhythm. MK-677 binds GHSR-1a receptors on somatotroph cells and in the hypothalamus, stimulating GH release and simultaneously suppressing somatostatin tone. Somatostatin is the primary brake on GH output.

That dual action matters. Tesamorelin pushes the accelerator; MK-677 partly releases the brake. The net result in animal models is a GH pulse that is both larger and longer-lasting than either compound produces alone [5]. In humans, a small crossover study (N=8) combining GHRH with the GHSR agonist GHRP-2 found GH AUC increased roughly four-fold compared to GHRH alone [6].

IGF-1 as the Practical Readout

GH itself has a half-life of about 20 minutes and oscillates too quickly to monitor clinically. IGF-1, produced in the liver in response to GH, has a half-life of 15 to 20 hours and serves as the integrated signal of total GH exposure over the prior 24 hours. Both individual trials above showed meaningful IGF-1 elevation. Stacking the agents may push IGF-1 above age-adjusted normal ranges, which is why monitoring at 8-week intervals matters more with the combination than with either drug alone.

Insulin Resistance: The Primary Shared Risk

GH is physiologically counter-regulatory to insulin. Both tesamorelin and MK-677 individually raise fasting glucose in a measurable fraction of subjects [2, 3]. Combining them additive risk is probable, not merely theoretical. Patients with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) face heightened risk of crossing into overt diabetes during this stack. The MK-677 trial in elderly patients reported a statistically significant increase in fasting glucose at 25 mg/day [3]. Tesamorelin's prescribing information specifically warns against use in patients with active diabetes when IGF-1 supraphysiologic levels are expected [2].

Complete Dosing Protocol

Tesamorelin Dose and Timing

The FDA-approved dose for tesamorelin is 2 mg subcutaneous injection once daily [2]. Most practitioners using tesamorelin off-label for body composition maintain this dose rather than escalating, because dose-escalation data beyond 2 mg are limited and adverse-effect risk rises with higher IGF-1.

Inject in the periumbilical subcutaneous tissue. Rotate sites within a 2-inch radius of the navel. Inject in the morning, before eating, to align with the natural GH-pulsatility window that peaks in early morning hours.

MK-677 Dose and Timing

MK-677's investigational dose range in published trials is 10 to 25 mg orally once daily [3, 4]. The 25 mg dose produced the largest IGF-1 elevation but also the most pronounced glucose increase. Practitioners commonly start at 10 mg nightly, assess IGF-1 and fasting glucose at 6 to 8 weeks, and step up to 25 mg only if IGF-1 remains below the upper limit of normal for age and fasting glucose stays below 100 mg/dL.

Dosing at night, 30 to 60 minutes before sleep, aligns MK-677 with the largest natural GH pulse that occurs in slow-wave sleep. Evening dosing may also reduce daytime lethargy, a common subjective complaint with morning dosing.

Cycle Length and Periodization

No clinical data define an optimal cycle length for this stack. The longest individual MK-677 trial ran 24 months [4]; the longest tesamorelin trial ran 52 weeks in extension cohorts [2]. Practitioner consensus, derived from structured patient-reported experience, clusters around 12 to 16 week on-cycles followed by 4 to 8 week off-cycles for combination use. This conservatism reflects the additive IGF-1 burden and the absence of long-term safety data for the stack specifically.

A practical periodization framework used at HealthRX for this combination:

| Phase | Duration | Tesamorelin | MK-677 | Monitoring | |---|---|---|---|---| | Ramp-up | Weeks 1 to 2 | 2 mg/day | 10 mg nightly | Baseline labs only | | Main cycle | Weeks 3 to 12 | 2 mg/day | 10 to 25 mg nightly | IGF-1, glucose at Week 6 | | Taper | Weeks 13 to 14 | 1 mg/day | 10 mg nightly | IGF-1 at Week 14 | | Off-cycle | Weeks 15 to 22 | None | None | HbA1c at Week 18 |

Monitoring Protocol

Laboratory Testing Schedule

Baseline testing before starting this stack should include: IGF-1 (age-adjusted), fasting glucose, HbA1c, comprehensive metabolic panel, and, in men over 40, fasting lipids and PSA. The Endocrine Society's 2019 guidelines on GH use recommend maintaining IGF-1 within age- and sex-adjusted normal limits during any GH-stimulating therapy [7].

Recheck IGF-1 and fasting glucose at 6 to 8 weeks after any dose change. If IGF-1 exceeds the upper limit of normal for the patient's age-sex cohort, reduce MK-677 to 10 mg or hold tesamorelin for two weeks before rechecking. If fasting glucose exceeds 125 mg/dL on two separate readings, discontinue both agents and refer for diabetes evaluation.

Clinical Symptoms to Watch

Carpal tunnel syndrome affects roughly 4% of tesamorelin-treated patients in the Phase III trials [2]. Swelling of the hands or paresthesias in the median nerve distribution (thumb, index, and middle fingers) should prompt dose reduction. Joint pain and peripheral edema are class effects of elevated GH and IGF-1 more broadly; both MK-677 and tesamorelin carry these risks individually.

Appetite stimulation with MK-677 is pronounced in most users. The ghrelin mimetic effect increases food intake acutely, particularly for carbohydrate-dense foods. Patients in the 2-year MK-677 trial gained a mean of 0.8 kg of fat mass at 25 mg/day, partially offsetting lean mass gains [4]. Dietary counseling concurrent with this stack is not optional.

Who Should Not Use This Stack

Active malignancy is an absolute contraindication to both agents. GH and IGF-1 can stimulate tumor proliferation; the FDA label for tesamorelin lists active malignancy as a contraindication [2]. Patients with uncontrolled type 2 diabetes should not combine these agents given the additive glucose burden documented in the individual trials. Pregnancy and breastfeeding are contraindications for both compounds.

Patients with a history of intracranial hypertension, acromegaly, or documented GH excess at baseline should not receive any GH-stimulating stack. Pituitary tumors or hypothalamic disease that alters GHRH or somatostatin signaling may produce unpredictable IGF-1 responses.

MK-677 has no approved indication and is classified by the FDA as an unapproved investigational drug [8]. It cannot lawfully be prescribed in the United States for body composition or anti-aging purposes. Tesamorelin is approved only for HIV-associated lipodystrophy; off-label use requires informed consent documentation and physician judgment about individual risk-benefit.

Evidence Gaps and Honest Limitations

The stack rationale is mechanistically coherent and supported by the individual Phase III datasets for each agent. No RCT has tested tesamorelin plus MK-677 as a combination, and none is currently registered on ClinicalTrials.gov as of January 2025.

The closest human evidence for a GHRH-plus-GHSR-agonist combination comes from acute stimulation testing studies, not from multi-week dosing trials [1, 6]. Long-term combined GH-axis stimulation over months carries theoretical risk of pituitary downregulation, though tachyphylaxis to GHRH analogs was not seen over 52 weeks in the tesamorelin extension study [2]. MK-677 receptor downregulation data in humans are not published.

The Endocrine Society's position statement on GH therapy in adults states: "GH therapy should target IGF-1 levels in the normal age- and sex-adjusted range to minimize risk of adverse effects, particularly insulin resistance and potential carcinogenicity" [7]. That standard applies with equal or greater force to off-label stacks lacking direct trial data.

Practical Injection and Administration Notes

Reconstituting Tesamorelin

Egrifta SV (the current U.S. Formulation) comes as a 2 mg lyophilized powder. Reconstitute with 2.1 mL sterile water for injection; the resulting solution is 1 mg/mL. Do not shake; swirl gently. Use within 24 hours if refrigerated. Inject immediately after drawing up the dose. Dispose of the vial after a single reconstitution.

MK-677 Formulation Considerations

MK-677 sourced outside a clinical trial is obtained through compounding pharmacies or research-chemical suppliers. Compounding-pharmacy preparations may carry a prescription pathway in some states; research-chemical sources are not pharmaceutical-grade and carry unknown purity risk. Published trial preparations used pharmaceutical-grade ibutamoren mesylate in oral capsule form [3]. Quality verification through certificate-of-analysis testing is advisable for any compounded or third-party-sourced material.

Drug Interactions

No pharmacokinetic interaction studies exist for tesamorelin plus MK-677. Both agents raise IGF-1, so concurrent use of other IGF-1-elevating compounds (sermorelin, CJC-1295, GHRP-2, GHRP-6, or exogenous GH) would multiply the IGF-1 burden further and is not recommended with this stack.

Tesamorelin may reduce the efficacy of drugs metabolized by cytochrome P450 enzymes if GH-mediated CYP3A4 induction occurs; the FDA label notes this interaction class [2]. Corticosteroids and estrogen-containing therapies reduce GH-axis responsiveness and may blunt the stack's intended effect [7]. Insulin and oral hypoglycemics may require dose adjustment given both agents' glucose-raising effects.